POINT Biopharma Corp. Employment AgreementEmployment Agreement • May 3rd, 2021 • Therapeutics Acquisition Corp. • Pharmaceutical preparations • Ontario
This Agreement (as defined below) sets out the terms and conditions of your employment by the Company and will constitute your employment agreement.
POINT Biopharma USA Inc. Employment AgreementTherapeutics Acquisition Corp. • May 3rd, 2021 • Pharmaceutical preparations • Delaware
This Agreement (as defined below) sets out the terms and conditions of your employment by the Company and will constitute your employment agreement.
EXCLUSIVE LICENSE AND COMMERCIALIZATION AGREEMENTExclusive License and Commercialization Agreement • May 3rd, 2021 • Therapeutics Acquisition Corp. • Pharmaceutical preparations • Ontario
This Exclusive License and Commercialization Agreement (this “Agreement”), dated as of 16 December 2020 (“Effective Date”), is made by and between POINT Biopharma Inc., having an address 4850 West 78th Street, Indianapolis, Indiana 46268, United States (“POINT”); Canadian Molecular Probe Consortium having a business office at C/O CPDC, Nuclear Research Building - A316, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1 (“CanProbe”); the Centre for Probe Development and Commercialization having a business office at Nuclear Research Building - A316, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1 (“CPDC”); and the University Health Network having a business office at 101 College Street, Suite 150, Heritage Building, MaRS Centre, Toronto, Ontario M5G 1L7 Canada (“UHN”). CanProbe, CPDC and UHN are collectively referred to herein as “Licensor”. Each of POINT, CanProbe, CPDC and UHN may be referred to herein as a “Party” or together as “Parties”.
POINT Biopharma USA Inc. Employment AgreementTherapeutics Acquisition Corp. • May 3rd, 2021 • Pharmaceutical preparations • New York
This Agreement (as defined below) sets out the terms and conditions of your employment by the Company and will constitute your employment agreement.
Supply Agreement – Lu-177-PNT2002Supply Agreement • May 3rd, 2021 • Therapeutics Acquisition Corp. • Pharmaceutical preparations
SUPPLY AGREEMENT (“Supply Agreement”) effective as of the date of last signing (“Effective Date”) between POINT Biopharma Corporation having a place of business at 22 St. Clair Ave. East, Suite 1201, Toronto, Ontario M4T 2S3 (“POINT”), and Centre for Probe Development and Commercialization having a place of business at McMaster University, Nuclear Research Building A316, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1, (“CPDC”), (together the “Parties” and each a “Party”). This document defines the terms and conditions under which CPDC will provide POINT the Product outlined in this Supply Agreement.
